TARGET VALIDATION AND EXPERIMENTAL ACTIVITY OF FUNCTIONALLY SUBSTITUTED 1,3,4-THIADIAZOLES: A CRITICAL SECONDARY ANALYSIS
Keywords:
1,3,4-thiadiazole; molecular docking; target validation; carrageenan-induced edema; alloxan-induced diabetes; critical appraisal.Abstract
Molecular docking and animal experiments have both been reported for functionally substituted 1,3,4-thiadiazoles, but interpretation requires careful alignment of computational targets with disease biology. Objective: To critically integrate previously published docking observations with in vivo anti-inflammatory and glucose-lowering findings while checking the identity of the deposited protein structures. Methods: A secondary narrative appraisal of three publications from 2024 was undertaken. Reported ligand identities, protein Data Bank codes, carrageenan-induced edema and alloxan-induced hyperglycemia outcomes were extracted without generating new docking scores or biological measurements. The target identifiers were checked against their Protein Data Bank records. Results: The original docking abstract identified diethyl 2,2′-((1,3,4-thiadiazole-2,5-diyl)bis(sulfanediyl))diacetate as a promising ligand, whereas an animal study highlighted the corresponding diacetohydrazide in assays of inflammation and glycemia. Critically, PDB 6W5C represents a Cas12i–RNA–DNA complex rather than a validated inflammatory target; PDB 2DSQ describes an insulin-like growth factor/IGF-binding protein complex, not a validated antidiabetic therapeutic target in the cited report. Conclusion: The animal results justify further investigation of selected thiadiazoles, but the docking claims cannot currently be taken as mechanistic confirmation. Re-docking against validated disease-relevant targets and independent experimental validation are needed.
References
1.Basirova, G. R. (2024). Молекулярный докинг производных 1,3,4 тиадиазола [Molecular docking of 1,3,4-thiadiazole derivatives]. Academic Research in Modern Science, 121–122. https://doi.org/10.5281/zenodo.13968337
2.Basirova, G. R., Zhaloliddinov, F. Yu., Makhmudov, L. U., & Babayev, B. N. (2024). Synthesis and pharmacological evaluation of new 1,3,4-thiadiazole derivatives. Science and Innovation, 3(11), 139–143. https://doi.org/10.5281/zenodo.14251419
3.Basirova, G. R., Makhmudov, L. U., Usmonov, Sh. T., Tagayalieva, N. A., & Babayev, B. N. (2024). Определение острой токсичности и воспалительной активности производных 1,3,4-тиадиазолов [Determination of acute toxicity and inflammatory activity of 1,3,4-thiadiazole derivatives]. Journal of IQRO, 13(1).
4.RCSB Protein Data Bank. Entry 6W5C: Cryo-EM structure of Cas12i(E894A)-crRNA-dsDNA complex. https://doi.org/10.2210/pdb6W5C/pdb
5.RCSB Protein Data Bank. Entry 2DSQ: Structural basis for the inhibition of insulin-like growth factors by IGF binding proteins. https://doi.org/10.2210/pdb2DSQ/pdb
6.OECD. (2002). Test No. 420: Acute Oral Toxicity—Fixed Dose Procedure. OECD Publishing. https://doi.org/10.1787/9789264070943-en
Austria
Uzbekistan
United States
United Kingdom
Germany
France
Italy
Spain
Turkey
Saudi Arabia
United Arab Emirates
Qatar
Egypt
Jordan
India
Pakistan
Bangladesh
China
Japan
South Korea
Malaysia
Indonesia
Kazakhstan
Kyrgyzstan
Tajikistan